<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366973</url>
  </required_header>
  <id_info>
    <org_study_id>P20-127</org_study_id>
    <nct_id>NCT04366973</nct_id>
  </id_info>
  <brief_title>A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers</brief_title>
  <acronym>NeoVie</acronym>
  <official_title>New Care Pathways to Achieve HCV Elimination in the Community: Real-world Outcomes From HCV Infected Patients Treated in Addiction Centers in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C Virus is liver disease and is a leading cause of death and morbidity with around
      71 million people affected worldwide. Widespread availability of highly effective
      direct-acting antivirals (DAAs) have dramatically changed the treatment landscape of HCV with
      a cure rate of over 95%. In May 2019, French Health Authorities expanded prescription
      abilities to all physicians treating adult treatment-naive patients with HCV without
      cirrhosis of the liver. This study will assess the treatment uptake and barriers to treatment
      by non-HCV specialist in France in community-based addiction centers. Beyond these
      evaluations, data on health resource utilization in addiction centers, level of knowledge of
      both patients and providers on HCV infection and treatment, care cascade, effectiveness and
      safety of Glecaprevir/Pibrentasvir among patients treated in addiction centers and evolution
      of addiction behavior after treatment are of specific interest.

      Glecaprevir/Pibrentasvir is a drug approved to treat HCV. About 400 Adult participants with a
      confirmed positive HCV ribonucleic acid (RNA) test will be enrolled in the study at
      approximately 30 addiction centers in France.

      All participants will attend an inclusion visit. Participants who are not prescribed
      Glecaprevir/Pibrentasvir at the inclusion visit will have no further follow-up in the study.
      Participants who are prescribed Glecaprevir/Pibrentasvir will take three tablets once daily.
      The duration of the study is approximately 12 months.

      All study visits will occur during routine clinical practice but there may be a higher burden
      for participants prescribed Glecaprevir/Pibrentasvir. These participants will be asked to
      complete questionnaires after each visit.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with and without Hepatitis C Virus (HCV) treatment prescribed at end of the inclusion visit.</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>Percentage of participants with and without HCV treatment prescribed at end of the inclusion visit. Criteria for treatment choice and reasons for treatment refusal will be described.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Care Resources and Utilization</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>HCRU in the addiction centers will be described on the basis of declarative questionnaires completed at time of the study implementation (yearly number of people followed, health resources, staffing, formation of center team, capabilities regarding HCV screening, specialized consultations in hepatology, and liver fibrosis tests).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of HCV infection knowledge</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>The level of knowledge of both patients and providers on HCV infection will be described on the basis of declarative questionnaires. For patients, analysis will be performed in the TP population and according to patient subgroups (with and without HCV treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determinants associated with initiation of HCV treatment</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>Criteria for treatment choice or no treatment uptake assessed by physician, patient, and disease characteristics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data and disease characteristics from patients with and without HCV treatment</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>Data and disease characteristics from patients with and without HCV treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with HCV Antibodies (HCV Ab)</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>Number of participants with HCV Antibodies (HCV Ab).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with HCV RNA</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>Number of participants with HCV RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from HCV Ab to HCV RNA</measure>
    <time_frame>Inclusion visit (Week 0)</time_frame>
    <description>Time from HCV Ab to HCV RNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from HCV RNA to end of treatment</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Time from HCV RNA to end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who completed treatment</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Number of participants who completed treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving SVR12</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>SVR12 defined as HCV RNA under the lower limit of quantification (LLOQ) 12 weeks after the last dose of treatment with a sensitive polymerase chain reaction (PCR) test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cured participants willing to share their experience with other substance abuse patients.</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Percentage of cured participants willing to share their experience with other substance abuse patients at the SVR12 visit and up to 6 months after the SVR12 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving sustained viral response at 12 weeks (SVR12)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Number of participants achieving sustained viral response at 12 weeks (SVR12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to SVR12</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Time to SVR12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of people in charge of patient follow-up</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Number of people in charge of patient follow-up including physicians, nurses, social workers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with treatment adherence</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Defined as the percentage of participants who have taken the target dose according to participant reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Quality of Life</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Anxiety and depression questionnaires and global assessment using visual analog scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with addictive behaviors</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Addictive behaviors of participants (alcohol and drug consumption) will be assessed by participant-completed questionnaires.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Participants with Hepatitis C Virus With or Without Treatment</arm_group_label>
    <description>This study includes 3 populations for analysis:
Target Population (TP): Defined as all participants enrolled in the study regardless of whether treated for HCV or not.
Core Population (CP): Defined as all participants of the TP who have been prescribed glecaprevir/pibrentasvir (G/P) and started treatment.
Safety Population (SP): Defined as all participants who received at least one dose of G/P.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants treated with glecaprevir/pibrentasvir for confirmed positive Hepatitis C
        Virus.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Followed in an addiction center.

          -  Confirmed positive for HCV ribonucleic acid (RNA).

        Exclusion Criteria:

          -  None.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yohann Gorrichon</last_name>
    <phone>+33 660529004</phone>
    <email>yohann.gorrichon@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de soin d'accompagnement et de prevention en addictologie- CHU Archet 2 /ID# 218682</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soin d'accompagnement et de prevention en addictologie-J.F C MENEZ /ID# 218684</name>
      <address>
        <city>Brest</city>
        <state>Bretagne</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soins d'accompagnement et de prevention en addictologie- EPINAL AVSEA /ID# 218677</name>
      <address>
        <city>Epinal</city>
        <state>Grand-Est</state>
        <zip>88000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centres de Soin d'Accompagnement et de Prevention en Addictologie-ANPAA 52 /ID# 218672</name>
      <address>
        <city>St Dizier</city>
        <state>Grand-Est</state>
        <zip>52100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soin d'accompagnement et prevention en addictologie-UTTD Montpellier /ID# 218683</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soin d'accompagnement et de prevention en addictologie-Paul Guiraud /ID# 218710</name>
      <address>
        <city>Bagneux</city>
        <state>Ile-de-France</state>
        <zip>92220</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centres de Soin d'Accompagnement et de Prevention en Addictologie-Les WADS CMSEA /ID# 218671</name>
      <address>
        <city>Metz</city>
        <state>Lorraine</state>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Hôpital Brabois Adultes /ID# 221515</name>
      <address>
        <city>Vandoeuvre les Nancy CEDEX</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Association Tremplain 17 -Saintes /ID# 218708</name>
      <address>
        <city>Saintes</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>17100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centres de Soin d'Accompagnement et de Prevention en Addictologie-AIPD 09 /ID# 218674</name>
      <address>
        <city>Foix</city>
        <state>Occitanie</state>
        <zip>09000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soins d'accompagnement et de prevention en addictologie-ANPAA 82 /ID# 218675</name>
      <address>
        <city>Montauban</city>
        <state>Occitanie</state>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soin d'accompagnement et de prevention en addictologie- L'ENVOL /ID# 218680</name>
      <address>
        <city>Nimes</city>
        <state>Occitanie</state>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie- Fréjus /ID# 218698</name>
      <address>
        <city>Frejus</city>
        <state>Provence-Alpes-Cote-d Azur</state>
        <zip>83600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins Accompagnement et de Prevention en Addictologie-Antibes /ID# 221277</name>
      <address>
        <city>Antibes</city>
        <zip>06600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centres de Soin d'Accompagnement et de Prevention en Addictologie -Bayonne /ID# 218673</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEID Bordeaux /ID# 221517</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Vinatier - Service universitaire d'addictologie de Lyon /ID# 218695</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand- Service d'addictologie /ID# 221278</name>
      <address>
        <city>Clermont Ferrand CEDEX 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie- Equinoxe /ID# 218702</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie- AVASTOFA /ID# 218709</name>
      <address>
        <city>La Seyne Sur Mer</city>
        <zip>83500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins Accompagnement et de Prevention en Addictologie-CICAT /ID# 221281</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins Accompagnement et de Prevention en Addictologie-Boris Vian /ID# 221284</name>
      <address>
        <city>Lille</city>
        <zip>59800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Bobillot - Limoges /ID# 221922</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins Accompagnement Prevention Addictologie-Hopital E. HERRIOT /ID# 218696</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie- CASANOVA /ID# 218705</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soins d'accompagnement et de prevention en addictologie-Mayenne /ID# 218676</name>
      <address>
        <city>Mayenne</city>
        <zip>53100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie- Arc en ciel /ID# 218700</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie-ANPAA 34 /ID# 221280</name>
      <address>
        <city>Montpellier</city>
        <zip>34080</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Caarud Axess /Id# 221282</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie- Malaussena /ID# 218703</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins Accompagnement et de Prevention en Addictologie- LOGOS /ID# 221283</name>
      <address>
        <city>Nimes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie-Nova Dona /ID# 221516</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEID Bearn addictions /ID# 221279</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie- L'Envol /ID# 218704</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de soin d'accompagnement et de prevention en addictologie -ITHAQUE /ID# 218678</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie-ANPAA 31 /ID# 218699</name>
      <address>
        <city>Toulouse</city>
        <zip>31200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Soins d'Accompagnement et de Prevention en Addictologie-Tempo Oppelia /ID# 218701</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>HCV</keyword>
  <keyword>glecaprevir/pibrentasvir</keyword>
  <keyword>Maviret</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

